Digestive Tract Cancer and CIPN

March 24, 2024 updated by: National Cheng-Kung University Hospital

The Effects of Remote Exercise Program in Patients With Digestive Tract Cancer and Chemotherapy-induced Peripheral Neuropathy

According to the incidence rate of cancer, the digestive tract cancer accounts for two of the top ten cancers. It also accounts for half of the top ten causes of cancer death. Chemotherapy remains one of the most common forms of cancer treatment, and chemotherapy-induced peripheral neuropathy (CIPN) is one of the common adverse effects of cancer treatment in cancer survivors. To date, there is no exercise guideline established for patients with CIPN; therefore, CIPN remains quite threatening to cancer survivors. Due to limited studies on effects of exercise on improvement of CIPN symptoms in patients with digestive tract cancers, this study aims to investigate the effects of exercise and different intervention delivery modes (remote home exercise and exercise under supervision) at different time points on the CIPN symptoms, body inflammatory index, physical function, and quality of life of gastrointestinal cancer survivors with chemotherapy-induced peripheral neuropathy.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Tainan, Taiwan, 701
        • Recruiting
        • Department of Physical Therapy, National Cheng-Kung University
        • Contact:
          • Cheng-Feng Lin, Ph.D

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Age 20 and above;
  2. Diagnosed by a physician with gastrointestinal cancer and has undergone chemotherapy or is currently undergoing chemotherapy;
  3. Diagnosed by a physician with chemotherapy-induced peripheral neuropathy.

Exclusion Criteria:

  1. Cognitive impairment or inability to cooperate with verbal instructions;
  2. Neurological, muscular, skeletal, or cardiovascular issues preventing participation in exercise training;
  3. Age 80 or above;
  4. Refusal to engage in exercise intervention or participate in data collection.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: remote home-based exercise therapy group

Location and Frequency: Four times per week at the individual's own home. Exercise Duration: Eight weeks (subject to adjustments based on actual progress), with a total exercise time of 40 minutes each session.

Exercise Components: Cardiovascular endurance exercise, resistance training, sensory exercises.

Note: The participant will receive a customized exercise plan based on their capabilities, including guidelines and exercise instructions (exercise names, required equipment, movement sequences, repetitions, precautions).

Location and Frequency: Four times per week at the individual's ownhome. Exercise Duration: Eight weeks (subject to adjustments based onactual progress), with a total exercise time of 40 minutes each session.

Exercise Components: Cardiovascular endurance exercise, resistancetraining, sensory exercises.

Note: The participant will receive a customized exercise plan based ontheir capabilities, including guidelines and exercise instructions (exercisenames, required equipment, movement sequences, repetitions,precautions).

Active Comparator: supervised exercise therapy group

Exercise Location and Frequency: Physiotherapy Center (twice a week) and individual's home (twice a week).

Exercise Duration: Eight weeks (subject to adjustments based on actual progress), with a total exercise time of 40 minutes each session.

Exercise Components: Cardiovascular endurance exercise, resistance training, sensory training exercises. The home-based exercise training content is partially the same as the remote home-based exercise group.

Exercise Location and Frequency: Physiotherapy Center (twice a week)and individual's home (twice a week).

Exercise Duration: Eight weeks (subject to adjustments based on actualprogress), with a total exercise time of 40 minutes each session.

Exercise Components: Cardiovascular endurance exercise, resistancetraining, sensory training exercises. The home-based exercise trainingcontent is partially the same as the remote home-based exercise group.

Other: regular care group
Perform regular care for eight consecutive weeks. After the tracking period ends (8 weeks), provide home-based education on resistance exercises, cardiovascular endurance exercises, and sensory training exercises.
Perform regular care for eight consecutive weeks. After the trackingperiod ends (8 weeks), provide home-based education on resistanceexercises, cardiovascular endurance exercises, and sensory trainingexercises.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Basic information
Time Frame: baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
Gender, date of birth, education level, survival days and status, exercise habit, alcohol consume history, smoking history, type of cancer, stage of cancer, start date of chemotherapy, number of chemotherapy sessions prior to intervention, chemotherapy drugs used, study period, and the subjects' medical history.
baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
gene
Time Frame: baseline
gene
baseline
body height
Time Frame: baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
body height in m
baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
body weight
Time Frame: baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
body weight in kg
baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
body mass index
Time Frame: baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
body mass index in kg/m2
baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
blood data
Time Frame: baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
blood data, including blood cell count, neutrophils, lymphocytes, monocytes, hemoglobin, albumin, magnesium, mean corpuscular volume, etc.
baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
Questionnaire of Quality of Life
Time Frame: baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) is to assess the quality of life. The transferred score range for this tool is typically from 0 to 100, where 0 indicates very poor quality of life, and 100 indicates very good quality of life. There are five aspects in the QLQ-C30, including physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning. In this scoring system, higher scores generally indicate better quality of life, while lower scores suggest poorer quality of life.
baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
Questionnaire of Chemotherapy-Induced Peripheral Neuropathy
Time Frame: baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
The European Organisation for Research and Treatment of Cancer Chemotherapy-Induced Peripheral Neuropathy 20-item scale (CIPN-20) assesses sensory abnormalities in patients. Scores range from 0 to 80, with 0 indicating no abnormalities and 80 severe abnormalities. Lower scores indicate better outcomes, while higher scores indicate worse outcomes. The total score is calculated by adding scores from items 1 to 19, ranging from 19 to 76, termed the CIPN20 sum1-19 score. Item 20 evaluates male impotence, relevant only for males. Additionally, items are categorized into sensory (1, 2, 3, 4, 5, 6, 9, 10, and 18), motor (7, 8, 11, 12, 13, 14, 15, and 19), and autonomic (16, 17, and 20) subscales.
baseline, 4-week intervention, 8-week intervention, and 3 month after intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle Strength
Time Frame: baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
Evaluate muscle strength using grip strength assessment device. Participant grips device withdominant hand using maximum effort.
baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
Dynamic Balance
Time Frame: baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
Use Timed Up & Go (TUG) test. Participant stands from chair upon signal, walks 3m at normal pace,returns, and sits. Time recorded
baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
Sensation Test
Time Frame: baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
Assess sensory issues from neuropathy using Romberg test
baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
Cardiovascular Endurance
Time Frame: baseline, 4-week intervention, 8-week intervention, and 3 month after intervention
Assess using 2-min step test. Participant steps in place for 2 mins, feet higher thanmidpoint between patella and iliac spine. Tester notes successful steps in 2 mins.
baseline, 4-week intervention, 8-week intervention, and 3 month after intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Cheng-Feng Lin, Ph.D, Department of Physical Therapy, National Cheng-Kung University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 19, 2023

Primary Completion (Estimated)

July 31, 2025

Study Completion (Estimated)

July 31, 2025

Study Registration Dates

First Submitted

December 11, 2023

First Submitted That Met QC Criteria

March 24, 2024

First Posted (Actual)

March 26, 2024

Study Record Updates

Last Update Posted (Actual)

March 26, 2024

Last Update Submitted That Met QC Criteria

March 24, 2024

Last Verified

August 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • B-ER-112-010

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chemotherapy-induced Peripheral Neuropathy

Clinical Trials on remote home-based exercise therapy group

Subscribe